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1. Metastatic colorectal cancer
The management of metastatic colorectal cancer (mCRC)
is becoming increasingly complex. With the potential
introduction of a further three new active treatments
over the next 12−18 months (aﬂibercept [AVE0005],
regorafenib [Bayer 73-4506], and possibly TAS-102), eight
classes of drug will be available to oncologists to treat
mCRC. Patients now frequently receive 5−6 lines of
therapy. These advances have improved outcomes to
such an extent that survival with ﬁrst-line treatment two
decades ago is now equivalent to the survival of patients
after modern third-line treatment.
As well as individualising treatment according to tra-
ditional patient (performance status, co-morbidities) and
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tumour (stage, biology, number and sites of metastases)
parameters, molecular biomarkers have enabled further
reﬁnements in the selection of patients for targeted
treatments. With the identiﬁcation of new prognostic
and predictive biomarkers, subgroups of patients with
a particularly poor prognosis are being identiﬁed who
seem to derive little beneﬁt from standard treatment
options and who may deteriorate more rapidly (e.g. EGFR
inhibitors in patients with KRASmut, BRAF, NRAS, PIK3CA
mutations 1−3). These patients may beneﬁt from other
treatment modalities.
1.1. Treatment of colorectal liver metastases
For patients with CRC liver metastases, multidisciplinary
teams tend to divide patients into three categories
according to the metastatic spread:
• <3−4 liver metastases (liver-limited disease): These
patients are typically identiﬁed as resectable or
potentially resectable. For those who are potentially
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resectable, neoadjuvant treatment allows a proportion
to be downsized for resection, but even in the best
operable cases with or without chemotherapy, half
will relapse by 14−18 months, many within the liver. 4
For these patients, the addition of organ-directed
neoadjuvant treatment may play a beneﬁcial role.
• 4+ liver metastases (liver-predominant disease): Ran-
domised surgical trials in this sub-group are lacking
and there is no consensus on the deﬁnition of
‘potentially operable’. Outcomes following liver surgery
are invariably compromised due to the development of
extra-hepatic disease, implying that systemic disease
is invariably present at the outset.
• Systemic disease and liver metastases: These are a
diverse group of patients with largely unresectable
liver disease with varying responses to chemotherapy
and targeted agents. Even so, a small percentage
achieve a good response to ﬁrst-line treatment with
systemic chemotherapy plus biologicals and recent
trials have shown that approximately 5−7% of patients
are subsequently considered candidates for surgical or
locoregional therapy. 5−7
1.2. The role of SIRT
For the majority of patients with unresectable colorectal
liver metastases, systemic chemotherapy is the only
treatment option. Based on the current experience, SIRT
should only be considered in the ﬁrst-line setting as part
of a clinical trial. 8 In the second-line setting, SIRT may
be considered as an adjunct to second-line therapy 9 or
for the consolidation of the response to ﬁrst-line therapy,
particularly in patients who have achieved an insufﬁcient
response for liver resection. SIRT may also have a
role in the second-line treatment of patients who are
responding poorly to chemotherapy and for whom the
prognosis is poor, such as tumours with BRAF mutations.
There is now good published (level 1 and 2) evidence
to support the use of SIRT in chemorefractory mCRC
(showing a prolonged time to progression with SIRT
compared with chemotherapy alone 10 and prolonged
survival compared with best supportive care 11).
2. Hepatocellular carcinoma
Currently the guidance to support the role of SIRT
in hepatocellular carcinoma (HCC) is based on level 2
evidence obtained from well-designed cohort or case–
control studies, often from one or more research group.
Prospective randomised clinical trials comparing SIRT
or SIRT followed by sorafenib versus sorafenib are now
ongoing, 12,13 which are expected to re-deﬁne the role of
SIRT in the treatment paradigm.
The decision to treat HCC is largely based on the
liver function status and tumour burden. For patients
who meet the Milan criteria (a single nodule up to 5 cm
or 3 small nodules up to 3 cm), there are three
radical treatment options (transplantation, resection
and ablation). 14−16 The treatment of choice is liver
transplantation for patients with early-stage disease and
cirrhosis within the appropriate age range and who lack
other comorbidities. 16 Otherwise, curative surgery is the
standard of care for HCC which meets the Milan criteria
in patients with a low risk of post-operative morbidity. 17
Ablation is an acceptable alternative to the resection for
lesions <3 cm, 18 and has low recurrence rates if ablative
tumour margins are at least 4−5mm. 19 However, even
with these options, there remain a small fraction of
patients with early-stage disease who are ineligible for
surgery due to the comorbidities or the location of the
tumour. For these patients, either SIRT or transarterial
chemoembolisation (TACE) are attractive alternatives.
Riaz and colleagues, in an analysis of tumours after
liver transplant, showed that SIRT achieved completed
necrosis in 89% of patients with tumours <3 cm and in
65% of patients with tumours between 3 and 5 cm. 20
For intermediate-stage (BCLC B) disease, TACE is the
standard of care for patients with good liver function
and disease that is not amenable to surgery, but who
are asymptomatic without vascular invasion or disease
beyond the liver. When broadly equivalent cohorts with
intermediate-stage HCC (BCLC B) were evaluated from
three independent studies, the overall survival for TACE
and SIRT was the same. 21−23 Published data also suggest
that SIRT has a more favourable proﬁle in terms of
health-related quality of life and health economics, 24−26
but before any deﬁnitive recommendations can be made,
the data from the ongoing comparative trial are needed.
For a subset of patients with intermediate-stage disease
(but beyond the Milan criteria), SIRT may also play a role
in downstaging disease. Investigators from Northwestern
University, Chicago, found that a higher proportion of
patients were downstaged from United Network for
Organ Sharing (UNOS) T3 to T2 with SIRT than TACE
(58% vs. 31%; p=0.023) resulting in a corresponding
improvement in median survival (censored 35.7 vs.
18.7 months; p=0.18; uncensored 41.6 vs. 19.2 months;
p=0.008). 27
For the most part, however, SIRT is used in the
multimodal treatment of intermediate- and advanced-
stage HCC in patients who are either ineligible for
or have progressed on prior treatment with surgery,
ablation or TACE/TAE. As such, these patients represent
a group of patients distinct from the cohorts previously
described. Centres with extensive experience using SIRT
have found that this procedure is effective for patients
with multinodular disease and/or portal vein invasion. 20
Further studies are ongoing to provide evidence for the
beneﬁts of SIRT in these populations compared to or in
combination with sorafenib.
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Fig. 1 – Integration of SIRT in the BCLC staging classiﬁcation and treatment schedule. Adapted from Llovet JM, Di Bisceglie AM,
Bruix J, et al. 31 Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698–711.
2.1. SIRT and treatment guidelines
The most recent guidelines from ESMO suggested that
SIRT may have a role as:
• a bridging option before other treatment modalities
or as a main therapy for diffuse intrahepatic tumour
spread;
• an alternative to TACE in selected patients with
contraindications to TACE;
• In relapse [patients who are] non-amenable to
surgery. 14
Both the National Comprehensive Cancer Network
Clinical Practice GuidelinesV.2.2010 15 and the Consensus
Recommendations of the National Cancer Institute
Clinical Trials Planning Meeting 28 are equally vague,
recommending locoregional treatments for: selected
patients with HCC conﬁned to the liver whose disease
is not amenable to resection or transplantation.
The latest guidelines from the American Association
for the Study of Liver Diseases (AASLD) 17 recognises that
SIRT “induces extensive tumour necrosis with acceptable
safety proﬁle” but notes that there are “no studies
demonstrating an impact on survival and hence, its
value in the clinical setting has not been established
and cannot be recommended as standard therapy for
advanced HCC outside clinical trials (level II)”. With the
publication of three large case series with SIRT since
these guidelines, 21−23 it is hoped that an amendment will
be made to this recommendation.
Meanwhile those who have experience with this
procedure in the clinic 21−23 recommend SIRT for patients
with liver-limited disease who are ineligible or are poor
candidates for TACE and before systemic treatment with
sorafenib (Fig. 1). 29,30
3. Neuroendocrine tumours
Although liver-directed ablative therapies for patients
with neuroendocrine liver metastases (NETLM) have
been successful for nearly 50 years, it is often the case
that appropriate patients are either not referred for liver
metastases treatment, or are considered very late in their
disease course. 32,33 No direct comparative clinical studies
have been completed comparing non-radiation embolic
therapy versus SIRT. However there is now solid level IIa
medical evidence in support of SIRT with and without
concurrent chemotherapy in NETLM, which eclipses
the many small series reported for TACE/TAE. Using
the European Neuroendocrine Tumour Society’s (ENETS)
Consensus Guidelines, it is appropriate to substitute
SIRT for those areas of the treatment algorithms
which list liver-ablative therapies, i.e. radiofrequency
ablation (RFA), laser-induced thermal therapy (LITT),
TACE, and TAE. 34 The North American Neuroendocrine
Tumor Society (NANETS) has a favourable view of
SIRT for NETLM. 35
3.1. Eligibility
It is appropriate to use SIRT in NETLM for the
following patients: asymptomatic and symptomatic
NETLM patients, with and without extrahepatic tumour.
Tumour debulking in, and stabilisation of, the liver
are the main endpoints of SIRT in NETLM patients.
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Secondary priority is decreased symptoms from tumour-
related syndromes. Survival is most often dependent
upon hepatic function and not death from syndrome
mediated organ failure. The most common clinical
scenario is of an asymptomatic or well-controlled
symptomatic patient with NETLM who is receiving long-
acting octreotide (Sandostatin). Many will have also
received prior chemotherapy and/or everolimus.
3.2. Treatment with SIRT
Response rates of SIRT are signiﬁcantly higher (75% vs.
16%) compared to Peptide Receptor Radiation Ther-
apy (PRRT). 33 SIRT is safe to use for patients who have
previously received PRRT or who are likely to receive
PRRT after SIRT for extrahepatic disease. 33
The standard requirements for SIRT are appropriate for
NETLM patients, but also added is use of short-acting
octreotide before, during and immediately after SIRT as
needed to control acute exacerbation of syndromes due
to rapid tumour lysis. In addition to tumour-speciﬁc
markers, follow-up studies include (if appropriate)
octreotide scintigraphy and axial imaging to monitor
response.
The majority of reports involving SIRT include fewer
than 70 patients, and are radiation-alone. However this
is similar to other ablative therapies for liver disease.
The current data support either concurrent 5-ﬂuorouracil
with SIRT or radiation alone for all subtypes of
NETLM. 32,33,36−38
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